Astellas Pharma (OTCMKTS:ALPMY) Posts Quarterly Earnings Results

Astellas Pharma (OTCMKTS:ALPMY) posted its quarterly earnings data on Wednesday. The company reported $0.13 EPS for the quarter, reports. Astellas Pharma had a net margin of 1.17% and a return on equity of 7.79%. The business had revenue of $3.11 billion during the quarter.

Astellas Pharma Trading Down 5.0 %

OTCMKTS ALPMY opened at $11.68 on Friday. The firm has a 50 day simple moving average of $11.96 and a 200-day simple moving average of $10.82. The company has a debt-to-equity ratio of 0.26, a quick ratio of 0.72 and a current ratio of 0.90. Astellas Pharma has a one year low of $9.15 and a one year high of $13.14. The firm has a market cap of $21.14 billion, a price-to-earnings ratio of 55.62 and a beta of 0.37.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.